Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCA | P06881 | 2/20 | 0.50 |
| ▸ | ADM2 | Q7Z4H4 | 8/20 | 0.47 |
| ▸ | CALCB | P10092 | 7/20 | 0.47 |
| ▸ | CALCRL | Q16602 | 10/20 | 0.46 |
| ▸ | RAMP1 | O60894 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL550614 | 1.00 | CALCA (0.50) | CALCAADM2CALCBCALCRLRAMP1 | |
| SCHEMBL29365536 | 1.00 | CALCA (0.50) | CALCAADM2CALCBCALCRLRAMP1 | |
| SCHEMBL260524 | 1.00 | CALCA (0.50) | CALCAADM2CALCBCALCRLRAMP1 | |
| SCHEMBL29368505 | 1.00 | CALCA (0.50) | CALCAADM2CALCBCALCRLRAMP1 | |
| SCHEMBL1819423 | 0.89 | CALCA (0.52) | CALCAADM2CALCBCALCRLRAMP1 | |
| SCHEMBL10246001 | 0.86 | CALCRL (0.51) | CALCAADM2CALCBCALCRLRAMP1 | |
| SCHEMBL31039442 | 0.85 | CALCRL (0.50) | CALCRLRAMP1 | |
| SCHEMBL978566 | 0.85 | CALCRL (0.50) | CALCRLRAMP1 | |
| SCHEMBL838209 | 0.85 | CALCRL (0.50) | CALCRLRAMP1 | |
| SCHEMBL977185 | 0.85 | CALCRL (0.50) | CALCRLRAMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3628045-B1 | COMPOUNDS | UNIV SHEFFIELD (GB) | 2024-07-03 | — | — | EP | disclosed |
| EP-3708566-B1 | NOVEL HETEROCYCLIC COMPOUNDS AND THE USE THEREOF IN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2023-02-08 | — | — | EP | disclosed |
| EP-3708566-B1 | NOVEL HETEROCYCLIC COMPOUNDS AND THE USE THEREOF IN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2023-02-08 | — | — | EP | disclosed |
| US-20230036854-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2023-02-02 | — | — | US | disclosed |
| US-20230036854-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2023-02-02 | — | — | US | disclosed |
| US-20220023281-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2022-01-27 | — | — | US | disclosed |
| US-20220023281-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2022-01-27 | — | — | US | disclosed |
| US-20210113534-A1 | COMPOUNDS | THE UNIVERSITY OF SHEFFIELD (GB) | 2021-04-22 | — | — | US | disclosed |
| EP-3708566-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THE USE THEREOF IN MEDICINE AND IN COSMETICS | Galderma Research & Development (FR) | 2020-09-16 | — | — | EP | disclosed |
| EP-3708566-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THE USE THEREOF IN MEDICINE AND IN COSMETICS | Galderma Research & Development (FR) | 2020-09-16 | — | — | EP | disclosed |
| US-20080318927-A1 | Substituted monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2008-12-25 | — | — | US | disclosed |
| US-20080318927-A1 | Substituted monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2008-12-25 | — | — | US | disclosed |
| WO-2008127584-A1 | CGRP RECEPTOR ANTAGONISTS WITH TERTIARY AMIDE, SULFONAMIDE, CARBAMATE AND UREA END GROUPS | MERCK & CO., INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008112159-A2 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008073251-A1 | CONSTRAINED SPIROCYCLIC COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008020902-A1 | SUBSTITUTED SPIROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007133491-A1 | SUBSTITUTED SPIROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070265225-A1 | Substituted monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
| US-20070265225-A1 | Substituted monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
| US-20070265225-A1 | Substituted monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318927-A1 | Substituted monocyclic CGRP receptor antagonists | EDNRB, CALCRL, QRFPR | CALCA 16/4885ADM2 146/4885CALCB 22/4885 |
| US-20210113534-A1 | COMPOUNDS | MRGPRX2, MC2R, ADM2 | CALCA 157/4885ADM2 3/4885CALCB 133/4885 |
| US-20230036854-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | MC2R, AGTR2, NR3C2 | CALCA 274/4885ADM2 6/4885CALCB 186/4885 |
| US-20070265225-A1 | Substituted monocyclic CGRP receptor antagonists | QRFPR, CALCRL, EDNRB | CALCA 16/4885ADM2 188/4885CALCB 23/4885 |
| US-20220023281-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | MC2R, AGTR2, AGTR1 | CALCA 244/4885ADM2 5/4885CALCB 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.